top of page

PARTNERING

At rAAVen, we work side-by-side with biopharma partners to solve one of the key challenges in gene therapy: efficient and selective in vivo delivery. Using our rAAptr platform, we design and screen tailored AAV capsid libraries aligned with a partner’s indication, target tissue, species, and route of administration.

Partnering Stages

De novo designed

AAV library

aav_library.png

​De novo library design:

10-10 million AAVs

  • Customized library

  • Designed for specific target/application

  • Screening in NHPs:    16 months

  • Delivery: Top capsids for validation

Screen existing

AAV library

screen_aavs.png

​Existing library:

10-100 million AAVs

  • Screen existing library

  • Validate function in multiple NHP tissues

  • Screening in NHPs:    12 months

  • Delivery: Top capsids for validation

Validate top

AAV Capsids

viruses.png

Validation of 5-20

rAAVen capsids

  • Validate top rAAVen capsids

  • Based on sequencing data from internal NHP screens

  • Screening in NHPs:    5 months

  • Delivery: Full validated capsid

Since our founding, we have entered into collaborations with Myrtelle Inc. and Prevail Therapeutics, supporting their discovery and optimization of new AAV vectors. 

We are open to flexible partnership models—from focused capsid discovery projects to broader, multi-program capsid portfolios. If you are exploring new delivery solutions for your gene therapy pipeline, we would be glad to discuss how we can work together. 

Myrtelle.png
cojourney_Logo-crop-1024x387.webp
redoxis-logo.png
VUGENE_logo.png

To discuss partnering opportunities, please contact info@raaven.se

bottom of page